alexa Rituximab: Is it Possible to Link Both Autoimmune Haemolytic Anemia and Aplastic Anemia Regarding the Etiology and Management? | Open Access Journals
ISSN: 2327-5146
General Medicine: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Rituximab: Is it Possible to Link Both Autoimmune Haemolytic Anemia and Aplastic Anemia Regarding the Etiology and Management?

Mina T. Kelleni*

Pharmacology Department, Faculty of Medicine, Minia University, Minia, Egypt

*Corresponding Author:
Kelleni MT, PhD, MD
Pharmacology department, Faculty of Medicine
Minia University, Minia, Egypt
Tel: +201200382422
Email: [email protected]

Received date: June 28, 2016; Accepted date: June 29, 2016; Published date: June 30, 2016

Citation: Kelleni MT (2016) Rituximab: Is it Possible to Link Both Autoimmune Haemolytic Anemia and Aplastic Anemia Regarding the Etiology and Management?. Gen Med (Los Angeles) 4:e110. doi:10.4172/2327-5146.1000e110

Copyright: © 2016 Kelleni MT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at General Medicine: Open Access

Editorial

In the past few years, rituximab has been recognized as a safe and effective emerging treatment for autoimmune hemolytic anemia (AIHA) [1,2]. Rituximab was also considered as a preferred secondline therapy of warm antibody hemolytic anemia in adults in some major European centers and it was shown that second-line treatment with rituximab led to response rates similar to splenectomy (approximately 70%) [3]. Further, a lower dose of rituximab, with satisfactory safety and efficacy, was better than the conventional glucocorticoid in the treatment of elderly AIHA patients [4].

In 2002, rituximab was suggested as a first-line treatment for pure red cell aplasia after allogeneic bone marrow transplantation [5]. Three years later, rituximab was used successfully for treatment of a 73-yearold female with aplastic anemia, and the use of anti-CD20 monoclonal antibody in aplastic anemia was suggested to warrant further investigation [6]. Meanwhile, rituximab was shown to induce remission in a 68-year-old female with severe aplastic anemia induced by fludarabine and cyclophosphamide treating her B-cell chronic lymphocytic leukemia [7]. In 2011, rituximab was shown to induce remission in a 1-yr-old Japanese male infant developed hepatitisassociated aplastic anemia [8]. Recently, rituximab plus autologous hemotopoietic stem cell transplantation were used for the treatment of CD5 positive diffuse large B cell lymphoma with AIHA [9].

From my point of view, the great and successful usage of rituximab in the management of AIHA warrants more focused research on its full of potentials successful usage in aplastic anemia management. Following the footprints of rituximab, I expect more secrets to be revealed in the pathogenesis of aplasitc anemia; secrets that may connect the two hematological disorders as regard to the etiology and revolutionize their management in the near future.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 9079
  • [From(publication date):
    June-2016 - Sep 20, 2017]
  • Breakdown by view type
  • HTML page views : 8998
  • PDF downloads :81
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords